AOD 9604 Research Guide

What is AOD 9604?

AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), with the addition of a tyrosine residue at the N-terminus. Developed by Monash University in Melbourne, Australia, this modified hGH fragment was designed to isolate the lipolytic (fat-metabolising) properties of growth hormone without its growth-promoting or diabetogenic effects.

The peptide consists of 16 amino acids and has a molecular weight of approximately 1,817 Da. Its design rationale was based on research indicating that the C-terminal region of hGH is responsible for its fat metabolism effects, while the N-terminal portion drives growth and insulin resistance.

Mechanism of Action

Lipolysis Pathway

AOD 9604 research has focused primarily on its lipolytic mechanisms. In vitro studies using adipose tissue models demonstrated that AOD 9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation). The peptide appears to act through the beta-3 adrenergic receptor pathway, enhancing the release of stored fatty acids from adipocytes.

Anti-Lipogenic Activity

Beyond stimulating fat breakdown, research has shown AOD 9604 inhibits the transformation of non-fatty food sources into body fat. Studies by Heffernan et al. demonstrated that the peptide reduces the incorporation of glucose into lipids in adipose tissue models, suggesting a dual mechanism of action affecting both fat mobilisation and storage.

Growth Hormone Receptor Interactions

Unlike full-length hGH, AOD 9604 does not bind to the growth hormone receptor in a way that activates the JAK2/STAT5 signalling cascade responsible for IGF-1 production and growth effects. This selective activity profile is what makes the peptide of particular interest for metabolic research separate from growth-related pathways.

Key Research Areas

Adipose Tissue Studies

Research by the Monash University group demonstrated dose-dependent lipolytic effects of AOD 9604 in both human and animal adipose tissue models. In obese mouse models (ob/ob mice), daily administration produced significant reductions in body fat mass without affecting lean tissue, food intake, or IGF-1 levels.

Cartilage Repair Research

More recent research has explored AOD 9604's potential in cartilage biology. In vitro studies showed the peptide stimulated proteoglycan and collagen production by chondrocytes. This line of investigation led to studies examining AOD 9604 in osteoarthritis models, where it demonstrated chondroprotective properties distinct from its metabolic effects.

Safety Profile Research

A notable feature of AOD 9604 research is its separation of lipolytic effects from growth-promoting and diabetogenic effects. Studies confirmed that AOD 9604 does not stimulate the production of IGF-1 or insulin antibodies, does not affect blood glucose homeostasis, and does not promote long-bone growth — addressing key safety concerns associated with full-length growth hormone administration.

Australian Research Context

AOD 9604 has particular significance in Australian peptide research, having been developed at Monash University. The Therapeutic Goods Administration (TGA) granted AOD 9604 GRAS (Generally Recognised As Safe) status for use as a food additive in 2019, reflecting the extensive safety data accumulated during its research history. This makes it one of the most well-characterised peptides in Australian preclinical research.

Handling and Storage

AOD 9604 is supplied as a white lyophilised powder. Storage recommendations:

• Lyophilised form: Store at -20°C in sealed vials, protected from light
• Short-term storage: 2-8°C for up to 4 weeks
• Reconstitution: Dissolve in sterile water or bacteriostatic water. Add solvent gently along the vial wall
• Post-reconstitution: Store at 2-8°C, use within 21 days
• Note: AOD 9604 is relatively stable compared to larger peptides due to its small size

See our storage and handling guide for general peptide storage best practices.

Research Considerations

• The 16-amino-acid size means AOD 9604 is susceptible to rapid enzymatic degradation in biological systems — consider protease inhibitors in cell culture studies
• Dose-response studies should account for the peptide's relatively short in vivo half-life
• When studying metabolic effects, control for IGF-1 levels to confirm separation from growth hormone-like activity
• The beta-3 adrenergic receptor expression varies across species — consider species-specific receptor density when translating findings